KSHN 001126
Alternative Names: KSHN-001126Latest Information Update: 25 Sep 2024
At a glance
- Originator Kashiv BioSciences
- Class Antineoplastics; Estradiol congeners; Estrenes; Fluorinated hydrocarbons; Sulfoxides
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer
Most Recent Events
- 20 Jun 2024 Shivanka Research in collaboration with Eric Solutions plans I trial in Healthy volunteers in US and India in June 2024 (PO) (NCT06467201)
- 14 Apr 2023 Pharmacodynamics data from a preclinical studies in Breast cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 21 Jul 2021 KSHN 001126 is available for licensing as of 21 Jul 2021. https://kashivbiosciences.com/company-overview/